HopeStage
Back to all studies
CompletedNCT02560324

Ramelteon for Sleep and Smoking Abstinence

About this titleRead the official source — NCT02560324
Medication studyAges 18–65United StatesAddiction
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
PhiladelphiaSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: September 2015
Recruitment status
Completed
Enrollment listed in the registry
140
Sponsor
University of Pennsylvania
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT02560324
Official title
Show the full official title

Repurposing Melatonin Receptor Agonists as Adjunct Treatments for Smoking Cessation

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Philadelphia

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is University of Pennsylvania, a university.

Did this study involve medication?

Yes. The study involved medication, including Ramelteon and Placebo.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies